Antibacterial Final Rule Defers To Doctors; Labeling Will Emphasize Testing
Executive Summary
FDA's final rule on labeling requirements for systemic antibacterials defers to doctors on prescribing decisions
You may also be interested in...
Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill
Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J
Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill
Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J
FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said